BDX

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Becton, Dickinson And Co.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
CEO
Thomas Polen
Employees
72000
Headquarters

1 Becton Dr
Franklin Lakes, New Jersey 07417-1815
Phone: 12018476800
www.bd.com

News

ANGO stock drops as jury sides with Becton Dickinson in patent dispute (NASDAQ:ANGO)
Nov 23, 2022 16:54pm

Healthcare equipment maker AngioDynamics, Inc. (ANGO) fell ~10% Wednesday after a Delaware district court jury found that some of its implantable port products violated certain U.S


Source:Seeking Alpha
NIO To $34? Plus This Analyst Sees $245 For Becton, Dickinson and Company
Nov 11, 2022 16:00pm

Piper Sandler cut the price target on Becton, Dickinson and Company (NYSE: BDX ) from $255 to $245. Piper Sandler analyst Jason Bednar maintained the stock with a Neutral. Becton, Dickinson shares gained 5% to close at $229.28 on Thursday. Deutsche Bank cut the price target for Norwegian Cruise Line Holdings Ltd. (NYSE: Full story available on Benzinga.com


Source:Benzinga
Becton Dickinson PT Lowered to $245 at Piper Sandler
Nov 11, 2022 11:55am

https://www.investing.com/news/pro/becton-dickinson-pt-lowered-to-245-at-piper-sandler-432SI-2941586


Source:Investing.com
Becton, Dickinson and Company (BDX) Q4 2022 Earnings Call Transcript | AlphaStreet
Nov 11, 2022 11:20am

Becton, Dickinson and Company (NYSE:BDX) Q4 2022 Earnings Call dated Nov. 10, 2022.


Source:AlphaStreet
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,700 Today
Nov 10, 2022 21:34pm

Becton, Dickinson (NYSE: BDX ) has outperformed the market over the past 20 years by 3.41% on an annualized basis producing an average annual return of 11.05%. Currently, Becton, Dickinson has a market capitalization of $65.26 billion. Buying $1000 In BDX: If … Full story available on Benzinga.com


Source:Benzinga
Becton Dickinson shares rise as revenue tops expectations By Investing.com
Nov 10, 2022 20:30pm

Becton Dickinson shares rise as revenue tops expectations


Source:Investing.com
Becton, Dickinson and Company (BDX) Q4 2022 Earnings Call Transcript
Nov 10, 2022 16:56pm

Becton, Dickinson and Company (NYSE:NYSE:BDX) Q4 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Francesca DeMartino - SVP & Head, IR Thomas Polen -…


Source:Seeking Alpha
Becton Dickinson Q4 Revenues Decline 2 Percent
Nov 10, 2022 14:44pm

The firm saw growth in its base life science business offset by a decline in COVID-only testing revenues.


Source:GenomeWeb
Becton Dickinson''s FY23 Guidance Trails Wall Street View Reflecting Foreign Currency Impact
Nov 10, 2022 13:59pm

Becton Dickinson and Co (NYSE: BDX ) reported Q4 FY22 revenues of $4.76 billion , down 1.8% Y/Y (up 2.3% on a currency-neutral basis), slightly better than the consensus of $4.72 billion. Revenue was driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral. Medical segment sales increased 5.8% Y/Y to $2.38 billion. Life Sciences segment … Full story available on Benzinga.com


Source:Benzinga
Becton, Dickinson sets FY23 outlook below consensus amid currency headwinds
Nov 10, 2022 12:08pm

With its Q4 financials for fiscal 2022, COVID-19 test maker Becton, Dickinson (BDX) exceeded Street forecasts on Thursday, but the company issued a lower-than-expected FY23…


Source:Seeking Alpha
Becton Dickinson Earnings in line, Revenue Beats In Q4 By Investing.com
Nov 10, 2022 11:52am

Becton Dickinson Earnings in line, Revenue Beats In Q4


Source:Investing.com
Becton, Dickinson and Company Q4 Profit Increases, beats estimates
Nov 10, 2022 11:52am

WASHINGTON (dpa-AFX) - Becton, Dickinson and Company (BDX) reported earnings for its fourth quarter that increased from last year and beat the Street estimates.The company''s bottom line totaled $2…


Source:Finanz Nachrichten
Becton Dickinson Reports In-Line Q4 EPS; Guides FY23 By Investing.com
Nov 10, 2022 11:51am

Becton Dickinson Reports In-Line Q4 EPS; Guides FY23


Source:Investing.com
Becton Dickinson stock down 1.3% premarket as Q4 earnings beat tempered by soft fiscal 2023 guidance
Nov 10, 2022 11:49am

Becton Dickinson & Co. stock undefined slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal…


Source:MarketWatch
Becton Dickinson raises quarterly dividend by 4.6% to 91 cents a share
Nov 10, 2022 11:36am

Becton Dickinson & Co. undefined said Thursday its board has approved a 4.6% increase in its quarterly dividend to 91 cents a share. The medical tech and…


Source:MarketWatch
Becton, Dickinson Q4 2022 Earnings Preview (NYSE:BDX)
Nov 09, 2022 17:12pm

Becton, Dickinson (BDX) is scheduled to announce Q4 earnings results on Thursday, November 10th, before market open.The consensus EPS Estimate is $2.74 (+5.8% Y/Y) and the consensus…


Source:Seeking Alpha
Becton Dickinson and Company (NYSE: BDX) Falls -0.13% In Recent Session, What Are The Points You Absolutely Need To Consider?
Nov 08, 2022 19:00pm

Becton Dickinson and Company (NYSE:BDX) price is hovering lower on Tuesday, November 08, dropping -0.13% below its previous close. A look at today’s price movement shows that the recent level at last check reads $220.94, with intraday deals fluctuating between $219.04 and $222.18. The company’s 5Y monthly beta was ticking 0.65 while its P/E ratio … Becton Dickinson and Company (NYSE: BDX) Falls -0.13% In Recent Session, What Are The Points You Absolutely Need To Consider? Read More »


Source:Stocks Register
Becton, Dickinson and Magnolia to collaborate on reducing blood culture contamination
Oct 18, 2022 11:42am

Becton, Dickinson (BDX) and Magnolia Medical Technologies have teamed up to co-market Magnolia Steripath Micro Initial Specimen Diversion Device. platforms.Steripath complements BD''s…


Source:Seeking Alpha
Becton, Dickinson, Biocorp team up for traceability of injectable drugs
Oct 18, 2022 09:41am

Becton, Dickinson and Company (BDX) and French medical device maker Biocorp are collaborating on using connected technology to track adherence for self-administered drug therapies,…


Source:Seeking Alpha
BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs
Oct 18, 2022 05:00am

Regulatory News: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics. To support biopharmaceutical


Source:Wallstreet:Online
Becton, Dickinson Stock: Buy In Now While You Can (NYSE:BDX)
Oct 12, 2022 11:32am

Becton, Dickinson and Company has had its stock battered down 17% in the past month. Check out why I think BDX stock is undervalued and is a buy.


Source:Seeking Alpha
Top 5 3rd Quarter Trades of BOENNING & SCATTERGOOD, INC.
Oct 11, 2022 23:00pm

Related Stocks: MSFT , AAPL , C , ABBV , BDX ,


Source:GuruFocus
Becton Dickinson To Rally 23%? This Analyst Predicts $210 For NVIDIA
Oct 11, 2022 16:57pm

Citigroup cut the price target on NVIDIA Corporation (NASDAQ: NVDA ) from $248 to $210. NVIDIA shares rose 1.2% to $118.12 on Tuesday. Stifel reduced the price target for Illinois Tool Works Inc. (NYSE: ITW ) from $192 to $188. Illinois Tool Works shares rose 1% … Full story available on Benzinga.com


Source:Benzinga
Becton, Dickinson and Company – Consensus Indicates Potential 21.5% Upside
Oct 10, 2022 13:25pm

Becton, Dickinson and Company with ticker code (BDX) now have 11 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 319 and 227 with the average target price sitting at 277.55. Given that the stocks previous close was at 228.4 this is indicating there is a potential upside of 21.5%. The day 50 moving average is 249.74 and the 200 moving average now moves to 252.51. The market capitalisation for the company is $63,504m. You can visit the company''s website by visiting: https://www.bd.com [stock_market_widget type="chart" template="basic" color="green" assets="BDX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $77,170m based on the market concensus. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.


Source:DirectorsTalk
Becton, Dickinson issues voluntary recall of sterilization containers – WSJ
Oct 07, 2022 19:21pm

Becton, Dickinson (BDX) has announced a voluntary recall of certain special containers that hospitals use to sterilize surgical tools after tests indicated breaches in some products…


Source:Seeking Alpha
Global Breast Tissue Markers Market to Develop at 8.3% CAGR during Forecast Period, notes TMR Study
Oct 03, 2022 13:33pm

WILMINGTON, DE / ACCESSWIRE / October 3, 2022 / Transparency Market Research Inc. - In 2021, the global breast tissue markers market size was worth US$ 2.5 Bn. The global market is anticipated to rise at 8.3% CAGR during the forecast period, from 2022 to 2031. By 2031, the global breast tissue markers market is estimated to touch valuation surpassing US$ 5.8 Bn. Increasing breast cancer cases have forced governments all over the world to raise awareness about the significance of early identification of breast cancer. In the coming years, this is anticipated to drive the growth of the global market for breast tissue markers. Breast tissue markers provide the surgeon with the benefit of locating and physically tagging the biopsy location, enabling him to detect and perform surgery more successfully. The conventional approach makes use of a typical stainless steel marker. In order to guarantee total patient satisfaction, more sophisticated breast tissue indicators, such as mineral-based and also partly bio-absorbable markers, are utilized.


Source:Accesswire
BD, Certest Biotec launch monkeypox test
Sep 26, 2022 13:06pm

Becton, Dickinson (BDX) and partner CerTest Biotec said on Monday their molecular polymerase chain reaction ((PCR)) assay for monkeypox virus was now commercially available…


Source:Seeking Alpha
Molecular Diagnostics Market to Reach US$ 37.19 Bn by 2028, TMR Study
Sep 26, 2022 12:33pm

WILMINGTON, DE / ACCESSWIRE / September 26, 2022 / Transparency Market Research Inc. - Rising use of automation in various healthcare and biotech research processes is creating attractive opportunities in the global molecular diagnostics market . This trend is further bolstered by the rising need for incorporating automation for facilitating various processes, including extraction of DNA, amplification, and analyzing and recording healthcare data. These automated systems offer various benefits, such as higher efficiency, precise output, and reduced time required for gaining results. Based on a recent research report, the global molecular diagnostics market is estimated to rise at a CAGR of 11.1% over the forecast period of 2021 to 2028. Get Exclusive PDF Sample Copy of Molecular Diagnostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783 Growing adoption of molecular diagnostic devices in various diagnostic laboratories, biotech and pharma companies, hospitals, and research and academic institutes is creating growth opportunities for players in the global molecular diagnostics market in developed economies.


Source:Accesswire
Closed-System Transfer Devices (CSTD) Market to Witness Huge Growth by Key Players: Becton Dickinson, Hospira, ICU Medical, Equashield, Corvida Medical
Sep 26, 2022 09:57am

The Closed-System Transfer Devices (CSTD) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement.


Source:OpenPR